Pfizer Pushes for Lyrica Patent Extension

Those who have been anxiously awaiting expiration of the patent for brand-name drug Lyrica, one of the top-prescribed drugs in workers’ comp, may have to wait a bit longer: Drugmaker Pfizer Inc. has reportedly received a six-month extension of its patent. The Lyrica patent had been scheduled to expire in December. But according to pharmacy benefit manager myMatrixx, the Food and Drug Administration delayed the expiration until June 30, 2019. The extension is related to “pediatric exclusivity” of the drug, myMatrixx clinical pharmacist Alan Rook said in a blog post. But what...